About Tralyte Health
Overview
Tralyte Health is a Virginia-based medical technology company advancing calcium measurement outside the clinic. We are developing a portable device designed to provide timely, accurate calcium measurement at home — beginning with hypoparathyroidism (“hypopara”), a rare chronic disease marked by rapid calcium fluctuations that can place patient stability at risk. By focusing first on one of the most demanding calcium conditions, we are establishing a disciplined foundation for broader electrolyte measurement over time. When treatment adjustments may be required the same day, access to timely data matters.
The Technology
The technology underlying Tralyte Health’s approach — the Ultrasensitive Separation-Free Blood Testing Method and Device — was developed over several years in a controlled laboratory setting by Dr. Xuewei Wang at Virginia Commonwealth University. The platform enables high-sensitivity biochemical measurement without traditional separation steps, supporting a new approach to portable electrolyte analysis. The technology is patent-pending and has been published in Analytical Chemistry (2023).
Dr. Wang's research was initially supported by the Orphan Disease Center at Penn Medicine and later advanced through competitive funding from Virginia Commonwealth University, Virginia Innovation Partnership Corporation, and the National Institutes of Health.
Leadership & Clinical Alignment
Our team (pictured here at our first engineering design meeting) brings together scientific, clinical, engineering, and entrepreneurial experience to guide responsible product development. We are committed to advancing this capability rigorously with long-term clinical relevance and scalability in mind.
Development Status
Tralyte Health is currently advancing engineering development of its first-generation calcium monitoring device. This is the "alpha prototype." Future stages will include clinical validation and regulatory pathway planning as the platform progresses.
